Concentrix (NASDAQ:CNXC) Price Target Lowered to $38.00 at Barrington Research

Concentrix (NASDAQ:CNXC) had its price target trimmed by Barrington Research from $62.00 to $38.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

CNXC has been the subject of a number of other research reports. Canaccord Genuity Group lowered their price objective on shares of Concentrix from $80.00 to $55.00 and set a “buy” rating for the company in a research report on Wednesday. Weiss Ratings cut Concentrix from a “hold (c-)” rating to a “sell (d)” rating in a research note on Thursday, January 29th. Wall Street Zen upgraded Concentrix from a “hold” rating to a “buy” rating in a report on Saturday, February 14th. Finally, Robert W. Baird dropped their price target on Concentrix from $52.00 to $40.00 and set an “outperform” rating on the stock in a research report on Wednesday. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $48.50.

Concentrix Stock Down 6.8%

Concentrix stock opened at $24.67 on Wednesday. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of -1.14, a PEG ratio of 0.28 and a beta of 0.50. The company’s 50 day simple moving average is $35.01 and its 200 day simple moving average is $40.22. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.18 and a quick ratio of 1.40. Concentrix has a fifty-two week low of $24.27 and a fifty-two week high of $66.00.

Concentrix (NASDAQ:CNXC) last issued its earnings results on Tuesday, March 24th. The company reported $2.61 EPS for the quarter, missing the consensus estimate of $2.65 by ($0.04). The firm had revenue of $2.50 billion during the quarter, compared to the consensus estimate of $2.49 billion. Concentrix had a negative net margin of 13.35% and a positive return on equity of 17.80%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.79 EPS. As a group, sell-side analysts anticipate that Concentrix will post 10.11 EPS for the current year.

Concentrix Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, May 5th. Investors of record on Friday, April 24th will be issued a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 5.8%. The ex-dividend date is Friday, April 24th. Concentrix’s payout ratio is presently -6.91%.

Insiders Place Their Bets

In other Concentrix news, CEO Christopher A. Caldwell purchased 1,000 shares of the stock in a transaction on Thursday, January 29th. The shares were purchased at an average price of $37.07 per share, with a total value of $37,070.00. Following the completion of the transaction, the chief executive officer directly owned 362,075 shares in the company, valued at $13,422,120.25. This represents a 0.28% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.90% of the stock is currently owned by company insiders.

Institutional Trading of Concentrix

Several hedge funds and other institutional investors have recently modified their holdings of CNXC. Royal Bank of Canada grew its position in shares of Concentrix by 9.5% in the first quarter. Royal Bank of Canada now owns 47,501 shares of the company’s stock valued at $2,643,000 after purchasing an additional 4,133 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Concentrix by 75.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 423,287 shares of the company’s stock worth $23,552,000 after purchasing an additional 181,546 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Concentrix by 17.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 146,515 shares of the company’s stock valued at $8,152,000 after buying an additional 21,746 shares during the period. Focus Partners Wealth bought a new position in Concentrix in the first quarter valued at approximately $781,000. Finally, Geneos Wealth Management Inc. increased its stake in shares of Concentrix by 532.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 620 shares of the company’s stock valued at $34,000 after purchasing an additional 522 shares during the last quarter. Institutional investors own 90.34% of the company’s stock.

Key Concentrix News

Here are the key news stories impacting Concentrix this week:

• Positive Sentiment: Revenue and business momentum — Q1 revenue rose 5.4% year-over-year and management cites strong enterprise iX Suite wins and continued AI adoption, showing demand for Concentrix’s higher-value solutions. GlobeNewswire: Q1 Results
• Positive Sentiment: Capital return actions — the company declared a $0.36 quarterly dividend (≈5.3% yield) and repurchased ~1M shares in Q1, supporting shareholder income and signaling confidence in the business. Dividend & buyback detail
• Neutral Sentiment: Company guidance maintained full-year revenue and non-GAAP EPS ranges, but Q2 guidance implies modest constant‑currency growth and lower near-term margins — investors are parsing the recovery timeline. See management’s outlook in the release. Guidance
• Neutral Sentiment: Analyst activity is mixed: several firms trimmed price targets but left buy/outperform ratings, creating dispersion in street expectations (see Benzinga summaries). Analyst PT changes
• Negative Sentiment: Margin compression and EPS miss — Q1 non-GAAP operating margin fell ~180–240 bps and GAAP EPS missed estimates; operating income and net income declined sharply (operating income down ~30%, net income down ~69%), which directly pressured the stock. Yahoo: Margin squeeze story
• Negative Sentiment: Cash-flow and leverage concerns — Q1 used cash from operations and adjusted free cash flow was negative; debt-related costs and recent early note redemption added charges. Analysts warn high leverage and negative near‑term FCF increase execution risk. QuiverQuant: cash flow & earnings detail
• Negative Sentiment: Analyst skepticism and downgrades — independent pieces and at least one downgrade argue the transition to AI-driven services is complex and costly, keeping a “hold” view until margins and cash flow recover in H2 2026. That contributed to selling pressure. Seeking Alpha: Downgrade
• Neutral Sentiment: Market data oddities — multiple short‑interest notices in feeds appear inconsistent (zero reported shares), so short‑interest signals are not reliable for today’s move. (Data sources cited in news entries.)

Concentrix Company Profile

Concentrix Inc (NASDAQ: CNXC) is a global business services company specializing in customer engagement solutions and technology‐driven business process outsourcing. The firm’s offerings encompass customer care delivered across voice and digital channels, back‐office processing, analytics and consulting, and automated workflow management. By integrating proprietary platforms, strategic partnerships and advanced automation, Concentrix helps clients enhance customer experiences and streamline operations.

Its capabilities extend to digital marketing and technology implementation, leveraging artificial intelligence, machine learning and data analytics to optimize customer journeys.